Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy

It has been suggested that in multifocal prostate cancer (PCa), focal therapy to the largest (index) lesion is sufficient, because secondary non-index lesions are unlikely to contribute to disease progression. In this study, the role of PCa focality in selecting men for focal therapy was evaluated. A histopathological analysis of the index and non-index lesions of 100 consecutive radical prostatectomy specimens was carried out. Cases that would have been suitable for focal ablation were also evaluated. Tumours were more often multifocal (78%) and bilateral (86%). In total, 270 tumour foci were identified. In multifocal disease, tumour volume, Gleason score and pathological stage were almost invariably defined by the index lesion of the specimen; among the 170 satellite foci, 148 (87%) were <0.5 cm3 and 169 (99.4%) had Gleason score ⩽6. Using the defined criteria, 51% of men in this series would have been considered suitable for focal ablation of the index lesion. Histological features of poor prognosis in the prostate are associated with the index lesion. There is a high proportion of patients who may be suitable for focal therapy, and clinical trials of index lesion ablation should be considered as part of this therapeutic strategy.

[1]  R. Jenkins,et al.  Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. , 1997, The Journal of urology.

[2]  D. Bostwick,et al.  Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. , 2007, Urology.

[3]  P. Scardino,et al.  1574: Is Focal Therapy Reasonable in Patients with Early Stage Prostate Cancer (CAP) - an Analysis of Radical Prostatectomy (RP) Specimens , 2006 .

[4]  J. Moul,et al.  Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. , 2007, Urology.

[5]  E. Bergstralh,et al.  Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. , 1996, The Journal of urology.

[6]  T. Stamey,et al.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.

[7]  M. Rubin,et al.  MAXIMUM TUMOR DIMENSION PROVIDES A CLINICALLY USEFUL AND INDEPENDENTLY SIGNIFICANT MEASURE FOR PREDICTING PSA-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY , 1999 .

[8]  C. Busch,et al.  Morphometric studies of intra-prostatic volume relationships in localized prostatic cancer. , 1997, British journal of urology.

[9]  U. Ferreira,et al.  Prostate cancer pathologic stage pT2b (2002 TNM staging system): does it exist? , 2006, International braz j urol : official journal of the Brazilian Society of Urology.

[10]  D. Johnston,et al.  Detailed mapping of prostate carcinoma foci , 2000, Cancer.

[11]  G. Miller,et al.  Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. , 1994, The Journal of urology.

[12]  P. Dahm,et al.  Comparison of Ultrasound-Guided Biopsies and Prostatectomy Specimens: Predictive Accuracy of Gleason Score and Tumor Site , 2001, Urologia Internationalis.

[13]  Oliver Sartor,et al.  Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. , 2007, The Journal of urology.

[14]  J. Moul,et al.  Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer , 2007, Cancer.

[15]  A. Semjonow,et al.  Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. , 2006, Cancer research.

[16]  E. Crawford,et al.  The Current Use and Future Trends of Focal Surgical Therapy in the Management of Localized Prostate Cancer , 2007, Cancer journal.

[17]  D. Johnston,et al.  A Streamlined Three-Dimensional Volume Estimation Method Accurately Classifies Prostate Tumors by Volume , 2003, The American journal of surgical pathology.

[18]  C. Roehrborn,et al.  Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. , 1999, The Journal of urology.

[19]  P. Scardino Focal therapy for prostate cancer , 2009, Nature Reviews Urology.

[20]  M. Marberger,et al.  Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. , 1999, Techniques in urology.

[21]  Hashim Uddin Ahmed,et al.  Will focal therapy become a standard of care for men with localized prostate cancer? , 2007, Nature Clinical Practice Oncology.

[22]  G. Miller,et al.  Molecular analysis of multifocal prostate cancer lesions , 1999, The Journal of pathology.

[23]  T. Stamey,et al.  Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. , 2003, The Journal of urology.

[24]  P. Carroll,et al.  Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE database. , 2005, The Journal of urology.

[25]  D J Ruiter,et al.  HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS , 1996, The Journal of pathology.